Investor Presentation Full Year 2021
73
Investor presentation Full year 2021
NorditropinⓇ is the market leader on the growth hormone
market
DKK
Historic reported sales
for NorditropinⓇ
40%
billion
14% -22%
7%
2%
8% -2%
9
30%
6
3
0
IIII
2016 2017 2018 2019 2020 2021
■Norditropin Growth at CER
Note: Company reported sales; CER: Constant exchange rates
20%
10%
NorditropinⓇ value leadership maintained
despite increasing competition
36.3%
0%
Nov
2016
Nov
Novo Nordisk
⚫Pfizer
2021
Eli Lilly
Roche
Merck Kgaa
Sandoz
-Other
Note: IQVIA, MAT value DKK, Nov 2021
Novo NordiskⓇ
Continue frequent launches with new
indications and device upgrades
Device portfolio
norditropin
simpleXx
somatropin (rDNA origin) injection
norditropin
flexpro
somatropin (rDNA origin injection
norditropin
nordilet
somatropin (rDNA origin) injection
norditropin
nordiflex™
somatropin (rDNA origin) injectionView entire presentation